Navigation Links
PBS-Bio uncovers how Unibioscreen drug kills cancer
Date:3/9/2011

MESA, Ariz. March 8, 2011 Predictive Biomarker Sciences (PBS-Bio) has uncovered how the experimental drug UNBS1450, produced by Unibioscreen, kills cancer cells.

Previous studies have shown that over-activity of a gene known as MCL1 can cause cancer cells to grow out of control. PBS-Bio, which is owned in part by the non-profit, Phoenix-based Translational Genomics Research Institute (TGen), co-discovered that UNBS1450 effectively shuts off the gene and induces apoptosis, the cancer cell's normal process of cellular death.

"It's a very nice candidate drug," said Dr. Michael Bittner, a biologist and Principal Investigator of the PBS-Bio technology. Dr. Bittner said UNBS1450 is effective against MCL1 in very low dosages, which means it could potentially be delivered to patients with minimal side effects and low toxicity. MCL1 is prevalent in leukemia, non-small-cell lung cancer, as well as cancers of the prostate and pancreas.

"The presence of MCL1 can be used as a stratification, or predictive, biomarker to help determine which cancer patients are most likely to respond to UNBS1450," said Dr. Edward Smith, co-founder and CEO of PBS-Bio. This would be particularly beneficial, Dr. Smith said, in selecting patients to participate in clinical trials of UNBS1450, and ultimately in helping physicians decide who should be placed on the drug once it is approved for general use.

Steve Weitman, Chief Medical Officer for Unibioscreen, based in Brussels, Belgium, said Unibioscreen has high hopes for the drug UNBS1450.

"Thanks to the critical assistance we received from PBS-Bio, we at Unibioscreen feel confident now that we have a potential biomarker that can be used to facilitate the development of UNBS1450," Weitman said.

In October, Unibioscreen announced it had entered into an agreement with PBS-Bio to get a more in depth understanding of the mechanisms involved in UNBS1450 as a means of optimizing cancer-patient treatment.

To jump-start drug development, PBS-Bio's analysis helps pharmaceutical companies better understand how their drugs work, and identifies biomarkers that can help predict which patients will respond to treatment.

PBS-Bio is providing drug companies with unique real-time looks at how new therapeutics actually work over time within cellular pathways the so-called mechanisms of action.

UNBS1450 has been in Phase I clinical trials at hospitals in Belgium and the Netherlands. The drug is a hemi-synthetic derivative of a compound identified by Unibioscreen in the root bark of a plant called Calotropis procera. Pre-clinical tests showed that UNBS1450 is very effective against various tumor types with no adverse side effects.


'/>"/>

Contact: Dr. Edward Smith
edsmith@pbs-bio.com
602-418-9300
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. TGen partner, PBS-Bio, makes first breakthrough drug analysis
2. Georgia Dentist Uncovers Obscure Law That Helps Dental Patients With Severe Anxiety
3. New Research Uncovers Elusive Target of Antifungal Agent
4. Purdue-IU team uncovers potential prostate cancer marker
5. Research uncovers extensive natural recovery after spinal cord injury
6. UCLA team uncovers mechanism behind organ transplant rejection
7. Quest for designer bacteria uncovers a Spy
8. Research uncovers a secret society connecting through the Internet
9. Research Uncovers Clue to SIDS
10. New York Truck Driver Watching Porn Kills Mother, Appalls Personal Injury Lawyers Such As David Perecman
11. Cognitive Skills May Shrink With Tamoxifen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Surgical Procedure Volumes: Global Analysis (United States, China, Japan, ... report to their offering. ... tool for healthcare business planners, provides surgical procedure volume ... surgery trends with an in-depth analysis of growth drivers ...
Breaking Medicine Technology: